ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1688

Evolution of Preclinical Autoimmunity in Individuals At Risk for Development of Rheumatoid Arthritis

Hani S. El-Gabalawy1, David B. Robinson1, Irene Smolik1, Donna M. Hart1, Elizabeth D. Ferucci2, Marianna M. Newkirk3, Marvin J. Fritzler4, Catriona Cramb5, Jeremy Sokolove6 and William H. Robinson7, 1Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, 2Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, 3Medicine, McGill University Health Centr, Montreal, QC, Canada, 4Medicine, University of Calgary, Calgary, AB, Canada, 5CCSR 4135 Immunology Rheumatol, Stanford University, Palo Alto, CA, 6Medicine, Stanford University, Palo Alto, CA, 7Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Native Americans, rheumatoid arthritis (RA) and risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Early Pathogenesis of Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is prevalent, severe, and predominantly seropositive in many North American Native (NAN) populations. We have shown a strong tendency towards familial clustering of RA, and high prevalence of RA autoantibodies and other risk factors in the first-degree relatives (FDR) of NAN RA patients. We have prospectively followed a large cohort of NAN FDR to better understand the preclinical events that lead to RA onset.

Methods: In total we recruited 310 FDR of NAN RA patients who were followed annually with questionnaires and joint examination. Plasma samples were gathered at each visit for biomarker analysis. Individuals who developed new joint symptoms between the annual visits were assessed, and the visit at which at least one swollen joint was detected was deemed to be the onset of inflammatory arthritis (IA). 

We used a custom multiplex bead-based autoantigen array on the BioPlex platform to analyze the profile of autoantibodies against citrullinated antigens exhibited by FDR at various time points prior to, and during, the period of disease onset.  The autoantigen targets were chosen based on proteomic analysis of synovial tissue and on previous analyses of a large number of RA patients and healthy controls. Levels of total circulating IgG and IgM immune complexes (IC) were measured using a C1q capture assay. 

Results: At the baseline visit, 22% FDR had anti-citrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF). This longitudinally followed cohort had a mean age at study enrollment of 35 ± 13 yrs. and 65% were female. Three FDR had definite RA at study entry and were followed as probands. Six FDR met the criteria for new onset IA after a median follow-up of 62 mo. (range 12-73). Of these 6 individuals, 2 were ACPA+ at baseline, one of whom was also RF+. In the period leading up to the development of IA, epitope spreading was evident in the ACPA response, with new targeting of citrullinulated epitopes from fibrinogen, vimentin, clustrin, biglycan. Notably, development of detectable IgM RF in most cases occurred subsequent to ACPA epitope spreading, and was within months of development of IA. An increase in IC levels was also detected in these FDR. A further 4 FDR demonstrated ACPA epitope spreading and had persistent arthralgia but no detectable synovitis at the time of reporting. To date, none of the 16% FDR who were initially RF+ but ACPA- have developed ACPA or IA. The 3 FDR who had RA at study entry were strongly positive for multiple ACPA autoantigens and did not demonstrate epitope spreading during the follow-up period.

Conclusion: The observations made in this prospectively followed cohort of high-risk NAN FDR who ultimately developed ACPA positive IA are consistent with the hypothesis that the autoimmune responses preceding the development of synovitis exhibit three stages: 1) initial breaking of immunological tolerance to citrullinated antigens; 2) epitope spreading of the ACPA response; and 3) development of RF. The latter event, which is likely associated with the formation of pathogenic immune complexes, may be the most proximal event preceding the development of clinically detectable synovitis. This hypothesis provides the framework for actionable stages of preclinical RA autoimmunity.


Disclosure:

H. S. El-Gabalawy,
None;

D. B. Robinson,
None;

I. Smolik,
None;

D. M. Hart,
None;

E. D. Ferucci,
None;

M. M. Newkirk,
None;

M. J. Fritzler,

Inova Diagnostics, Inc.,

5;

C. Cramb,
None;

J. Sokolove,
None;

W. H. Robinson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evolution-of-preclinical-autoimmunity-in-individuals-at-risk-for-development-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology